PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation

Biological Reviews

Volumn 92, Issue 4, 2017, Pages 2046-2069

  Zolezzi, Juan M ^a   Santos, Manuel J ^a   Bastías Candia, Sussy ^b   Pinto, Claudio ^a   Godoy, Juan A ^a   Inestrosa, Nibaldo C ^a,c,d  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSIDAD DE TARAPACÁ   (Chile)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSIDAD DE MAGALLANES   (Chile)

Author keywords

ageing; neurodegeneration; neuroinflammation; PPARs; SPPARM

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ALZHEIMER DISEASE; ANIMAL; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; METABOLISM; PARKINSON DISEASE; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; CENTRAL NERVOUS SYSTEM; HUMANS; HUNTINGTON DISEASE; INFLAMMATION; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;

EID: 85013371563     PISSN: 14647931     EISSN: 1469185X     Source Type: Journal    
DOI: 10.1111/brv.12320     Document Type: Article

References (349)

1. Aagaard, M. M., Siersbæk, R. & Mandrup, S. (2011). Molecular basis for gene-specific transactivation by nuclear receptors. Biochimica et Biophysica Acta 1812, 824–835.
2. Adams, M., Montague, C. T., Prins, J. B., Holder, J. C., Smith, S. A., Sanders, L., Digby, J. E., Sewter, C. P., Lazar, M. A., Chatterjee, V. K. & O'Rahilly, S. (1997). Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. Journal of Clinical Investigation 100, 3149–3153.
3. Ahmad, W. (2013). Overlapped metabolic and therapeutic links between alzheimer and diabetes. Molecular Neurobiology 47, 399–424.
4. Akiyama, H., Arai, T., Kondo, H., Tanno, E., Haga, C. & Ikeda, K. (2000). Cell mediators of inflammation in the Alzheimer diseased brain. Alzheimer Disease & Associated Disorders 14, S47–S53.
5. Aktas, O., Ullrich, O., Infante-Duarte, C., Nitsch, R. & Zipp, F. (2007). Neuronal damage in brain inflammation. Archives of Neurology 64, 185–189.
6. Allred, C. D. & Kilgore, M. W. (2005). Selective activation of PPARγ in breast, colon, and lung cancer cell lines. Molecular and Cellular Endocrinology 235, 21–29.
7. Asayama, K., Sandhir, R., Sheikh, F. G., Hayashibe, H., Nakane, T. & Singh, I. (1999). Increased peroxisomal fatty acid beta-oxidation and enhanced expression of peroxisome proliferator-activated receptor-alpha in diabetic rat liver. Molecular and Cellular Biochemistry 194, 227–234.
8. Auwerx, J., Schoonjans, K., Fruchart, J. C. & Staels, B. (1996). Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis 124, S29–37.
9. Balch, W. E., Morimoto, R. I., Dillin, A. & Kelly, J. W. (2008). Adapting proteostasis for disease intervention. Science 319, 916–919.
10. Balint, B. L. & Nagy, L. (2006). Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases. Endocrine, Metabolic & Immune Disorders - Drug Targets 6, 33–43.
11. Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D. & Jones, E. (2011). Alzheimer's disease. Lancet 377, 1019–1031.
12. 2+ signals and neuronal death in brain ischemia. Stroke 38, 674–676.
13. Bars, R. G., Bell, D. R. & Elcombe, C. R. (1993). Induction of cytochrome P450 and peroxisomal enzymes by clofibric acid in vivo and in vitro. Biochemical Pharmacology 45, 2045–2053.
14. Bastías-Candia, S., Garrido, N. A., Zolezzi, J. M. & Inestrosa, N. C. (2016). Recent advances in neuroinflammation therapeutics: PPARs/LXR as neuroinflammatory modulators. Current Pharmaceutical Design 22, 1312–1323.
15. Basu-modak, S., Braissant, O., Escher, P., Desvergne, B., Honegger, P. & Wahli, W. (1999). Peroxisome proliferator-activated receptor beta regulates acyl-CoA synthetase 2 in reaggregated rat brain cell cultures. Journal of Biological Chemistry 274, 35881–35888.
16. Beal, M. F. (2005). Mitochondria take center stage in aging and neurodegeneration. Annals of Neurology 58, 495–505.
17. Beato, M., Herrlich, P. & Schütz, G. (1995). Steroid hormone receptors: many actors in search of a plot. Cell 83, 851–857.
18. Beli, P., Lukachchunk, N., Wagner, S. A., Weinbert, B. T., Olsen, J. V., Baskcomb, L., Mann, M., Jackson, S. P. & Choudhardy, C. (2012). Proteomic investigations reveal a role for RNA processing factor THRAP3 in the DNA damage response. Molecular Cell 46, 212–225.
19. Bell, D. R. & Elcombe, C. R. (1991). Induction of acyl-CoA oxidase and cytochrome P450IVA1 RNA in rat primary hepatocyte culture by peroxisome proliferators. Biochemical Journal 280, 249–253.
20. Benjamin, S., Flotho, S., Börchers, T. & Spener, F. (2013). Conjugated linoleic acid isomers and their precursor fatty acids regulate peroxisome proliferator-activated receptor subtypes and major peroxisome proliferator responsive element-bearing target genes in HepG2 cell model. Journal of Zhejiang University. Science. B 14, 115–123.
21. Bernardo, A. & Minghetti, L. (2008). Regulation of glial cell functions by PPAR-gamma natural and synthetic agonists. PPAR Research 2008, 864140–864150.
22. Besson, V. C., Chen, X. R., Plotkine, M. & Marchand-Verrecchia, C. (2005). Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, exerts neuroprotective effects in traumatic brain injury. Neuroscience Letters 288, 7–12.
23. Blanquart, C., Mansouri, R., Fruchart, J. C., Staels, B. & Glineur, C. (2004). Different ways to regulate the PPARalpha stability. Biochemical and Biophysical Research Communications 319, 663–670.
24. Boehm-Cagan, A. & Michaelson, D. M. (2014). Reversal apoE4-driven brain pathology and behavioral deficits by bexarotene. Journal of Neuroscience 34, 7293–7301.
25. Bomben, V., Holth, J., Reed, J., Cramer, P., Landreth, G. & Noebels, J. (2014). Bexarotene reduces network excitability in models of Alzheimer's disease and epilepsy. Neurobiology of Aging 35, 2091–2095.
26. Bonifati, V. (2014). Genetics of Parkinson's disease--state of the art, 2013. Parkinsonism & Related Disorders 20, S23–S28.
27. Bordet, R., Ouk, T., Petrault, O., Gele, P., Gautier, S., Laprais, M., Deplanque, D., Duriez, P., Staels, B., Fruchart, J. C. & Bastide, M. (2006). PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochemical Society Transactions 34, 1341–1346.
28. 2-protein impairs synaptic remodeling and memory consolidation. Neurobiology of Aging 34, 1315–1327.
29. Braissant, O., Foufelle, F., Scotto, C., Dauca, M. & Wahli, W. (1996). Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137, 354–366.
30. Braissant, O. & Wahli, W. (1998). Differential expression of peroxisome proliferator-activated receptor –alpha, -beta, and -gamma during rat embryonic development. Endocrinology 139, 2748–2754.
31. Brauer, R., Bhaskaran, K., Chaturvedi, N., Dexter, D. T., Smeeth, L. & Douglas, I. (2015). Glitazone treatment and incidence of Parkinson's disease among people with diabetes: a retrospective cohort study. PLoS Medicine 12, e1001854.
32. Breidert, T., Callebert, J., Heneka, M. T., Landreth, G., Launay, J. M. & Hirsch, E. C. (2002). Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. Journal of Neurochemistry 82, 615–624.
33. Burns, K. A. & Vanden Heuvel, J. P. (2007). Modulation of PPAR activity via phosphorylation. Biochimica et Biophysica Acta 1771, 952–960.
34. Cameron, B. & Landreth, G. E. (2010). Inflammation, microglia, and Alzheimer's disease. Neurobiology of Disease 37, 503–509.
35. Camp, H. S. & Tafuri, S. R. (1997). Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase. Journal of Biological Chemistry 272, 10811–10816.
36. Cantó, C. & Auwerx, J. (2012). FGF21 takes a fat bite. Science 336, 675–676.
37. Carta, A. R. & Pisanu, A. (2013). Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease? Neurotoxicity Research 23, 112–123.
38. Carta, A. R., Pisanu, A. & Carboni, E. (2011). Do PPAR-γ agonists have a future in Parkinson's disease therapy? Parkinson's Disease 2011, 689181.
39. Carvalho, C., Correira, S. C., Cardoso, S., Plácido, A. I., Candeias, E., Duarte, A. I. & Moreira, P. I. (2015). The role of mitochondrial disturbances in Alzhemier, Parkinson and Huntington diseases. Expert Review of Neurotherapeutics 15, 867–884.
40. Caspersen, C., Wang, N., Yao, J., Sosunov, A., Chen, X., Lustbader, J. W., Xu, H. W., Stern, D., McKhann, G. & Yan, S. D. (2005). Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB Journal 19, 2040–2041.
41. Cauwe, B., Van den Steen, P. E. & Opdenakker, G. (2007). The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Critical Reviews in Biochemistry and Molecular Biology 42, 113–185.
42. Cerpa, W., Dinamarca, M. C. & Inestrosa, N. C. (2008). Structure-function implications in Alzheimer's disease: effect of Abeta oligomers at central synapses. Current Alzheimer Research 5, 233–243.
43. Chan, B. Y., Gartland, A., Wilson, P. J., Buckley, K. A., Dillon, J. P., Fraser, W. D. & Gallagher, J. A. (2007). PPAR agonists modulate human osteoclast formation and activity in vitro. Bone 40, 149–159.
44. Chaturvedi, R. K. & Beal, M. F. (2013). Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases. Molecular and Cellular Neuroscience 55, 101–114.
45. Chawla, A., Repa, J. J., Evans, R. M. & Mangelsdorf, D. J. (2001). Nuclear receptors and lipid physiology: opening the X-files. Science 294, 1866–1870.
46. Chen, X. R., Besson, V. C., Palmier, B., Garcia, Y., Plotkinc, M. & Marchand-Leroux, C. (2007). Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury. Journal of Neurotrauma 24, 1119–1131.
47. Chen, N. G. & Han, X. (2001). Dual function of troglitazone in ICAM-1 gene expression in human vascular endothelium. Biochemical and Biophysical Research Communications 282, 717–722.
48. Chen, L. W., Horng, L. Y., Wu, C. L., Sung, H. C. & Wu, R. T. (2012). Activating mitochondrial regulator PGC-1α expression by astrocytic NGF is a therapeutic strategy for Huntington's disease. Neuropharmacology 63, 719–732.
49. Chen, Z. & Zhong, C. (2012). Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Progress in Neurobiology 108, 21–43.
50. Chiang, M. C., Cheng, Y. C., Chen, H. M., Liang, Y. J. & Yen, C. H. (2014). Rosiglitazone promotes neurite outgrowth and mitochondrial function in N2A cells via PPARgamma pathway. Mitochondrion 14, 7–17.
51. Choi, J. H., Banks, A. S., Estall, J. L., Kajimura, S., Boström, P., Laznik, D., Ruas, J. L., Chalmers, M. J., Kamenecka, T. M., Blüher, M., Griffin, P. R. & Spiegelman, B. M. (2010). Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466, 451–456.
52. Christianson, J. L., Nicoloro, S., Straubhaar, J. & Czech, M. P. (2008). Stearoyl-CoA desaturase 2 is required for peroxisome proliferator-activated receptor gamma expression and adipogenesis in cultured 3T3-L1 cells. Journal of Biological Chemistry 283, 2906–2916.
53. Chu, A. J. (2005). Tissue factor mediates inflammation. Archives of Biochemistry and Biophysics 440, 123–132.
54. Ciechanover, A., Orian, A. & Schwartz, A. L. (2000). Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays 22, 442–451.
55. Cole, S. L. & Vassar, R. (2007). The basic biology of BACE1: a key therapeutic target for Alzheimer's disease. Current Genomics 8, 509–530.
56. Collino, M., Aragno, M., Mastrocola, R., Gallicchio, M., Rosa, A. C., Dianzani, C., Danni, O., Thiemermann, C. & Fantozzi, R. (2006). Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. European Journal of Pharmacology 530, 70–80.
57. Colville-Nash, P. R., Qureshi, S. S., Willis, D. & Willoughby, D. A. (1998). Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: correlation with induction of heme oxygenase 1. Journal of Immunology 161, 978–984.
58. Combs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B. & Landreth, G. E. (2000). Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. Journal of Neuroscience 20, 558–567.
59. Compe, E., Drané, P., Laurent, C., Diedrich, K., Braun, C., Hoeijmakers, J. H. & Egly, J. M. (2005). Dysregulation of the peroxisome proliferator-activated receptor target genes by XPD mutations. Molecular and Cellular Biology 25, 6065–6076.
60. Corona, A. W., Kodoma, N., Casali, B. T. & Landreth, G. E. (2016). ABCB1 is necessary for bexarotene-mediated clearance of soluble amyloid beta from hippocampus of APP/PS1 mice. Journal of Neuroimmune Pharmacology 11, 61–72.
61. Cramer, P. E., Cirrito, J. R., Wesson, D. W., Daniel Lee, C. Y., Colleen, K. J., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., Brunden, K. R., Wilson, D. A. & Landreth, G. E. (2012). ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 335, 1503–1506.
62. Cunard, R., Dicampli, D., Archer, D. C., Stevenson, J. L., Ricote, M., Glass, C. K. & Kelly, C. J. (2002a). WY14,643, a PPARα ligand, has profound effects on immune responses in vivo. Journal of Immunology 169, 6806–6812.
63. Cunard, R., Ricote, M., Dicampli, D., Archer, D. C., Kahn, D. A., Glass, C. K. & Kelly, C. J. (2002b). Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. Journal of Immunology 168, 2795–2802.
64. Cuzzocrea, S. (2004). Peroxisome proliferator-activated receptors gamma ligands and ischemia and reperfusion injury. Vascular Pharmacology 41, 187–195.
65. Cuzzocrea, S., Bruscoli, S., Mazzon, E., Crisafulli, C., Donato, V., Di Paola, R., Velardi, E., Esposito, E., Nocentini, G. & Riccardi, C. (2007). PPAR-{alpha} contributes to the anti-inflammatory activity of glucocorticoids. Molecular Pharmacology 73, 323–337.
66. Cuzzocrea, S., Mazzon, E., Di Paola, R., Peli, A., Bonato, A., Britti, D., Genovese, T., Muia, C., Crisafulli, C. & Caputi, A. P. (2006). The role of the peroxisome proliferator-activated receptor-alpha (PPAR-alpha) in the regulation of acute inflammation. Journal of Leukocyte Biology 79, 999–1010.
67. D'Agostino, G., La Rana, G., Russo, R., Sasso, O., Iacono, A., Esposito, E., Raso, G. M., Cuzzocrea, S., Lo Verme, J., Piomelli, D., Meli, R. & Calignano, A. (2007). Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan-induced paw edema in mice. Journal of Pharmacology and Experimental Therapeutics 322, 1137–1143.
68. Daniel, B., Nagy, G. & Nagy, L. (2014). The intriguing complexities of mammalian gene regulation: how to link enhancers to regulated genes. Are we there yet? FEBS Letters 588, 2379–2391.
69. Danzer, K. M., Haasen, D., Karow, A. R., Moussaud, S., Habeck, M., Giese, A., Kretzschmar, H., Hengerer, B. & Kostka, M. (2007). Different species of alpha-synuclein oligomers induce calcium influx and seeding. Journal of Neuroscience 27, 9220–9232.
70. Dasgupta, S., Roy, A., Jana, M., Hartley, D. M. & Pahan, K. (2007). Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-alpha. Molecular Pharmacology 72, 934–946.
71. Davidson, M. H., Armani, A., McKenney, J. M. & Jacobson, T. A. (2007). Safety considerations with fibrate therapy. The American Journal of Cardiology 99, 3C–18C.
72. De Felice, F. G. (2013). Alzheimer's disease and insulin resistance: translating basic science into clinical applications. Journal of Clinical Investigation 123, 531–539.
73. Dehmer, T., Heneka, M. T., Sastre, M., Dichgans, J. & Schulz, J. B. (2004). Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. Journal of Neurochemistry 88, 494–501.
74. Delerive, P., Wu, Y., Burris, T. P., Chin, W. W. & Suen, C. S. (2002). PGC-1 functions as a transcriptional coactivator for the retinoid X receptors. Journal of Biological Chemistry 277, 3913–3917.
75. Desvergne, B. & Wahli, W. (1999). Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Reviews 20, 649–688.
76. Dhar, A., Gardner, J., Borgmann, K., Wu, L. & Ghorpade, A. (2006). A novel role of TGF-beta in differential astrocyte-TIMP-1 regulation: implications for HIV-1-dementia and neuroinflammation. Journal of Neuroscience Research 83, 1271–1280.
77. Dickey, A. S., Pineda, V. V., Tsunemi, T., Liu, P. P., Miranda, H. C., Gilmore-Hall, S. K., Lomas, N., Sampat, K. R., Buttgereit, A., Manalang Torres, M.-J., Flores, A. L., Arreola, M., Arbez, N., Akimov, S. S., Gaasterland, T., Lazarowski, E. R., Ross, C. A., Yeo, G. W., Sopher, B. L., Magnuson, G. K., Pinkerton, A. B., Masliah, E. & La Spada, A. R. (2016). PPARδ repression in Huntington's disease and its essential role in CNS translate into a potent agonist therapy. Nature Medicine 22, 37–45.
78. Dinamarca, M. C., Ríos, J. A. & Inestrosa, N. C. (2012). Postsynaptic receptors for amyloid-β oligomers as mediators of neuronal damage in Alzheimer's disease. Frontiers in Physiology 3, 464.
79. Diradourian, C., Girard, J. & Pégorier, J. P. (2005). Phosphorylation of PPARs: from molecular characterization to physiological relevance. Biochimie 87, 33–38.
80. Dreyer, C., Krey, G., Keller, H., Givel, F., Helftenbein, G. & Wahli, W. (1992). Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68, 879–887.
81. Dunn, F. L., Higgins, L. S., Fredrickson, J. & DePaolib, A. M. (2011). Selective modulation of PPARg activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes. Journal of Diabetes and its Complications 25, 151–158.
82. Elgass, K., Pakay, J., Ryan, M. T. & Palmer, C. S. (2012). Recent advances into understanding of mitochondrial fission. Biochimica et Biophysica Acta 1833, 150–161.
83. Esmaeili, M. A., Yadav, S., Gupta, R. K., Waggoner, G. R., Deloach, A., Calingasan, N. Y., Beal, M. F. & Kiaei, M. (2016). Preferential PPAR-α activation reduces neuroinflammation, and blocks neurodegeneration in vivo. Human Molecular Genetics 25, 317–327.
84. Evans, R. M. (1988). The steroid and thyroid hormone receptor superfamily. Science 240, 889–895.
85. Feige, J. N., Gelman, L., Michalik, L., Desvergne, B. & Wahli, W. (2006). From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Progress in Lipid Research 45, 120–159.
86. Floyd, Z. E. & Stephens, J. M. (2002). Interferon-gamma-mediated activation and ubiquitin-proteasome-dependent degradation of PPARgamma in adipocytes. Journal of Biological Chemistry 277, 4062–4068.
87. Forman, B. M., Chen, J. & Evans, R. M. (1997). Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proceedings of the National Academy of Sciences of the United States of America 94, 4312–4317.
88. Frisardi, V. (2014). Impact of metabolic syndrome on cognitive decline in older age: protective or harmful, where is the pitfall? Journal of Alzheimer's Disease 41, 163–167.
89. Fruchart, J. C. (2013). Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists. Cardiovascular Diabetology 12, 82.
90. Fuentealba, R. A., Farias, G., Scheu, J., Bronfman, M., Marzolo, M. P. & Inestrosa, N. C. (2004). Signal transduction during amyloid-beta-peptide neurotoxicity: role in Alzheimer disease. Brain Research. Brain Research Reviews 47, 275–289.
91. Fuenzalida, K., Quintanilla, R., Ramos, P., Piderit, D., Fuentealba, R. A., Martinez, G., Inestrosa, N. C. & Bronfman, M. (2007). Peroxisome proliferator-activated receptor γ up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. Journal of Biological Chemistry 282, 37006–37015.
92. Fukao, T., Lopaschuk, G. D. & Mitchell, G. A. (2004). Pathways and control of ketone body metabolism: on the fringe of lipid biochemistry. Prostaglandins, Leukotrienes & Essential Fatty Acids 70, 243–251.
93. Furukawa, K., Matsuzaki-Kobayashi, M., Hasegawa, T., Kikuchi, A., Sugeno, N., Itoyama, Y., Wang, Y., Yao, P. J., Bushlin, I. & Takeda, A. (2006). Plasma membrane ion permeability induced by mutant alphasynuclein contributes to the degeneration of neural cells. Journal of Neurochemistry 97, 1071–1077.
94. Geldmacher, D. S., Fritsch, T., McClendon, M. J. & Landreth, G. (2011). A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Archives of Neurology 68, 45–50.
95. Genovese, T., Mazzon, E., Di Paola, R., Cannavo, G., Muia, C., Bramanti, P. & Cuzzocrea, S. (2005). Role of endogenous ligands for the peroxisome proliferators activated receptors alpha in the secondary damage in experimental spinal cord trauma. Experimental Neurology 194, 267–278.
96. Germain, P., Iyer, J., Zechel, C. & Gronemeyer, H. (2002). Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature 415, 187–192.
97. Gilardi, F., Giudici, M., Mitro, N., Maschi, O., Guerrini, U., Rando, G., Maggi, A., Cermenati, G., Laghezza, A., Loiodice, F., Pochetti, G., Lavecchia, A., Caruso, D., De Fabiani, E., Bamberg, K. & Crestani, M. (2014). LT175 is a novel PPARα/γ ligand with potent insulin sensitizing effects and reduced adipogenic properties. Journal of Biological Chemistry 289, 6908–6920.
98. Ginsberg, H. N., Elam, M. B., Lovato, L. C., Crouse, J. R. III, Leiter, L. A., Linz, P., Friedewald, W. T., Buse, J. B., Gerstein, H. C., Probstfield, J., Grimm, R. H., Ismail-Beigi, F., Bigger, J. T., Goff, D. C. Jr., Cushman, W. C., Simons-Morton, D. G. & Byington, R. P. (2010). Effects of combination lipid therapy in type 2 diabetes mellitus. New England Journal of Medicine 362, 1563–1574.
99. Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C. & Gage, F. H. (2010). Mechanisns underlying inflammation in neurodegeneration. Cell 140, 918–934.
100. Godoy, J. A., Rios, J. A., Zolezzi, J. M., Braidy, N. & Inestrosa, N. C. (2014a). Signaling pathway cross talk in Alzheimer's disease. Cell Communication and Signaling 28, 12–23.
101. Godoy, J. A., Zolezzi, J. M., Braidy, N. & Inestrosa, N. C. (2014b). Role of Sirt1 during the ageing process: relevance to protection of synapses in the brain. Molecular Neurobiology 50, 744–756.
102. Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, U. & Sawchak, S. (2010). Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dementia and Geriatric Cognitive Disorders 30, 131–146.
103. Gold, P. W., Licinio, J. & Pavlatou, M. G. (2013). Pathological parainflammation and endoplasmic reticulum stress in depression: potential translational targets through the CNS insulin, klotho and PPAR-γ systems. Molecular Psychiatry 18, 154–165.
104. Gosselin, D. & Glass, C. K. (2014). Epigenomics of macrophages. Immunological Reviews 262, 96–112.
105. Gottlicher, M., Widmark, E., Li, Q. & Gustafsson, J. A. (1992). Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proceedings of the National Academy of Sciences of the United States of America 89, 4653–4657.
106. Grau, R., Punzon, C., Fresno, M. & Iniguez, M. A. (2006). Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1. Biochemical Journal 395, 81–88.
107. Green, S. (1995). PPAR: a mediator of peroxisome proliferator action. Mutation Research 333, 101–109.
108. Green, S., Tugwood, J. D. & Issemann, I. (1992). The molecular mechanism of peroxisome proliferator action: a model for species differences and mechanistic risk assessment. Toxicology Letters 64-65 Spec No, 131–139.
109. Grey, A., Bolland, M., Gamble, G., Wattie, D., Horne, A., Davidson, J. & Reid, I. R. (2007). The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. The Journal of Clinical Endocrinology and Metabolism 92, 1305–1310.
110. Griffin, W. S., Sheng, J. G., Royston, M. C., Gentleman, S. M., McKenzie, J. E., Graham, D. I., Roberts, G. W. & Mrak, R. E. (1998). Glial-neuronal interactions in Alzheimer's disease: the potential role of a cytokine cycle in disease progression. Brain Pathology 8, 65–72.
111. Haass, C. & Selkoe, D. J. (2007). Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nature Reviews Molecular Cell Biology 8, 101–112.
112. Halliday, G. M., Leverenz, J. B., Schneider, J. S. & Adler, C. H. (2014). The neurobiological basis of cognitive impairment in Parkinson's disease. Movement Disorders 29(5), 634–650.
113. Han, J., Hajjar, D. P., Tauras, J. M., Feng, J., Gotto, A. M. Jr. & Nicholson, A. C. (2000). Transforming growth factor-beta1 (TGF-beta1) and TGF-beta2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-gamma. Journal of Biological Chemistry 275, 1241–1246.
114. Harrington, C., Sawchak, S., Chiang, C., Davies, J., Donovan, C., Saunders, A. M., Irizarry, M., Jeter, B., Zvartau-Hind, M., Van Dyck, C. H. & Gold, M. (2011). Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. Current Alzheimer Research 8, 592–606.
115. Hashimoto, T., Cook, W. S., Qi, C., Yeldani, A. V., Reddy, J. K. & Rao, M. S. (2000). Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid pxidation determinaes the severity of hepatic steatosis in response to fasting. Journal of Biological Chemistry 275, 28918–28928.
116. Hauser, S., Adelmant, G., Sarraf, P., Wright, H. M., Mueller, E. & Spiegelman, B. M. (2000). Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. Journal of Biological Chemistry 275, 18527–18533.
117. Helsen, C. & Claessens, F. (2014). Looking at nuclear receptors from a new angle. Molecular and Cellular Endocrinology 382, 97–106.
118. Hemmer, B. & Hartung, H. P. (2007). Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Annals of Neurology 62, 314–326.
119. Heneka, M. T., Klockgether, T. & Feinstein, D. L. (2000). Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. Journal of Neuroscience 20, 6862–6867.
120. Heneka, M. T. & Landreth, G. E. (2007). PPARs in the brain. Biochimica et Biophysica Acta 1771, 1031–1045.
121. Heneka, M. T., Landreth, G. E. & Hull, M. (2007). Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders. Nature Clinical Practice Neurology 3, 496–504.
122. Heneka, M. T., O'Banion, M. K., Terwel, D. & Kummer, M. P. (2010). Neuroinflammatory processes in Alzheimer's disease. Journal of Neural Transmission 117, 919–947.
123. Higgins, L. S. & Depaoli, A. M. (2010). Selective peroxisome proliferator-activated receptor g (PPARg) modulation as a strategy for safer therapeutic PPARg activation. The American Journal of Clinical Nutrition 91, 267S–272S.
124. Hoek, R. M., Ruuls, S. R., Murphy, C. A., Wright, G. J., Goddard, R., Zurawski, S. M., Blom, B., Homola, M. E., Streit, W. J., Brown, M. H., Barclay, A. N. & Sedgwick, J. D. (2000). Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290, 1768–1771.
125. Hollenberg, A. N. (2012). Metabolic health and nuclear-receptor sensitivity. New England Journal of Medicine 366, 1345–1347.
126. Huang, W., András, I. E., Rha, G. B., Hennig, B. & Toborek, M. (2011). PPARα and PPARγ protect against HIV-induced MMP-9 overexpression via caveolae-associated ERK and Akt signaling. FASEB Journal 25, 3979–3988.
127. Huang, W., Eum, S. Y., András, I. E., Hennig, B. & Toborek, M. (2009). PPARalpha and PPARgamma attenuate HIV-induced dysregulation of tight junctions proteins by modulations of matrix metalloproteinase and proteasome activities. FASEB Journal 23, 1596–1606.
128. Iankova, I., Petersen, R. K., Annicotte, J. S., Chavey, C., Hansen, J. B., Kratchmarova, I., Sarruf, D., Benkirane, M., Kristiansen, K. & Fajas, L. (2006). Peroxisome proliferator-activated receptor gamma recruits the positive transcription elongation factor b complex to activate transcription and promote adipogenesis. Molecular Endocrinology 20, 1494–1505.
129. Inestrosa, N. C., Carvajal, F. J., Zolezzi, J. M., Tapia-Rojas, C., Serrano, F., Karmelic, D., Toledo, E. M., Toro, A., Toro, J. & Santos, M. J. (2013). Peroxisome proliferators reduce spatial memory impairment, synaptic failure, and neurodegeneration in brains of a double transgenic mice model of Alzheimer's disease. Journal of Alzheimer's Disease 33, 941–959.
130. Inestrosa, N. C., Godoy, J. A., Quintanilla, R. A., Koenig, C. S. & Bronfman, M. (2005). Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling. Experimental Cell Research 304, 91–104.
131. Inoue, H., Jiang, X. F., Katayama, T., Osada, S., Umesono, K. & Namura, S. (2003). Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice. Neuroscience Letters 352, 203–206.
132. Issemann, I. & Green, S. (1990). Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645–650.
133. Itoh, T., Fairall, L., Amin, K., Inaba, Y., Szanto, A., Balint, B. L., Nagy, L., Yamamoto, K. & Schwabe, J. W. (2008). Structural basis for the activation of PPARγ by oxidized fatty acids. Nature Structural & Molecular Biology 15, 924–931.
134. Itoh, K., Nakamura, K., Iijima, M. & Sesaki, H. (2012). Mitochondrial dynamics in neurodegeneration. Trends in Cell Biology 23, 64–71.
135. Jackson, S. M., Parhami, F., Xi, X. P., Berliner, J. A., Hsueh, W. A., Law, R. E. & Demer, L. L. (1999). Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arteriosclerosis, Thrombosis, and Vascular Biology 19, 2094–2104.
136. Jekabsone, A., Mander, P. K., Tickler, A., Sharpe, M. & Brown, G. C. (2006). Fibrillar beta-amyloid peptide Abeta1-40 activates microglial proliferation via stimulating TNF-alpha release and H2O2 derived from NADPH oxidase: a cell culture study. Journal of Neuroinflammation 3, 24.
137. Jennewein, C., Kuhn, A. M., Schmidt, M. V., Meilladec-Julling, V., von Knethen, A., Gonzales, F. J. & Brüne, B. (2008). Sumoylation of peroxisome proliferator-activated receptor gamma by apoptotic cells prevents lipopolysaccharide-induced NCoR removal from kappaB binding sites mediating transrepression of proinflammatory cytokines. Journal of Immunology 181, 5646–5652.
138. Jiang, Q., Lee, C. Y., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., Richardson, J. C., Smith, J. D., Comery, T. A., Riddell, D., Holtzman, D. M., Tontonoz, P. & Landreth, G. E. (2008). ApoE promotes the proteolytic degradation of Aβ. Neuron 12, 681–693.
139. Jiang, C., Ting, A. T. & Seed, B. (1998). PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82–86.
140. Jin, J., Albertz, J., Guo, Z., Peng, Q., Rudow, G., Troncoso, J. C., Ross, C. A. & Duan, W. (2013). Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease. Journal of Neurochemistry 125, 410–419.
141. Kanakasabai, S., Pestereva, E., Chearwae, W., Gupta, S. K., Ansari, S. & Bright, J. J. (2012). PPARγ agonists promote oligodendrocyte differentiation of neural stem cells by modulating stemness and differentiation genes. PLoS One 7, e50500.
142. Kapadia, R., Yi, J. H. & Vemuganti, R. (2008). Mechanism of anti-inflammatory and neuroprotective actions of PPAR-gamma agonist. Frontiers in Bioscience 13, 1813–1826.
143. Kemp, S., Wei, H. M., Lu, J. F., Braiterman, L. T., McGuinness, M. C., Moser, A. B., Watkins, P. A. & Smith, K. D. (1998). Hene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy. Nature Medicine 4, 1261–1268.
144. Kendall, C. & Wooltorton, E. (2006). Rosiglitazone (Avandia) and macular edema. Canadian Medical Association Journal 174, 623.
145. Kersten, S., Seydoux, J., Peters, J. M., Gonzales, F. J., Desvergne, B. & Wahli, W. (1999). Peroxisome proliferator-activated receptors alpha mediates the adaptative response to fasting. Journal of Clinical Investigation 103, 1489–1498.
146. Kharroubi, I., Lee, C. H., Hekerman, P., Darville, M. I., Evans, R. M., Eizirik, D. L. & Cnop, M. (2006). BCL-6: a possible missing link for anti-inflammatory PPAR-delta signaling in pancreatic beta cells. Diabetologia 49, 2350–2358.
147. Kim, M. K., Chae, Y. N., Kim, H. S., Choi, S. H., Son, M. H., Kim, S. H., Kim, J. K., Moon, H. S., Park, S. K., Shin, Y. A., Kim, J. G., Lee, C. H., Lim, J. I. & Shin, C. Y. (2009). PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention. Archives of Pharmacal Research 32, 721–727.
148. Kim, Y. S. & Joh, T. H. (2006). Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Experimental & Molecular Medicine 38, 333–347.
149. Kim, T. H., Kim, M. Y., Jo, S. H., Park, J. M. & Ahn, Y. H. (2013). Modulation of the transcriptional activity of peroxisome proliferator-activated receptor gamma by protein-protein interactions and post-translational modifications. Yonsei Medical Journal 54, 545–559.
150. Kimura, O., Kondo, Y. & Shimosegawa, T. (2012). PPAR could contribute to the pathogenesis of hepatocellular carcinoma. PPAR Research 2012, 574180.
151. Kishi, T., Hirooka, Y. & Sunagawa, K. (2012). Telmisartan protects against cognitive decline via up-regulation of brain-derived neurotrophic factor/tropomyosin-related kinase B in hippocampus of hypertensive rats. Journal of Cardiology 60, 489–494.
152. Klegeris, A. & McGeer, P. L. (2005). Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. Current Alzheimer Research 2, 255–265.
153. Kliewer, S. A., Forman, B. M., Blumberg, B., Ong, E. S., Borgmeyer, U., Mangelsdorf, D. J., Umesono, K. & Evans, R. M. (1994). Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proceedings of the National Academy of Sciences of the United States of America 91, 7355–7359.
154. Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M. & Lehmann, J. M. (1997). Fatty acids and eicosanoids regulate gene expression through direct interaction with peroxisome proliferator-activated receptors alpha and gamma. Proceedings of the National Academy of Sciences of the United States of America 94, 4318–4323.
155. Kocalis, H. E., Turney, M. K., Printz, R. L., Laryea, G. N., Muglia, L. J., Davies, S. S., Stanwood, G. D., McGuinness, O. P. & Niswender, K. D. (2012). Neuron-specific deletion of peroxisome proliferator-activated receptor delta (PPARδ) in mice leads to increased susceptibility to diet-induced obesity. PLoS One 7, e42981.
156. Koistinaho, M. & Koistinaho, J. (2005). Interactions between Alzheimer's disease and cerebral ischemia—focus on inflammation. Brain Research Reviews 48, 240–250.
157. Krohn, M., Lange, C., Hofrichter, J., Scheffler, K., Stenzel, J., Steffen, J., Schumacher, T., Brüning, T., Plath, A. S., Alfen, F., Schmidt, A., Winter, F., Rateitschak, K., Wree, A., Gsponer, J., Walker, L. C. & Phanke, J. (2011). Cerebral amyloid-β proteostasis is regulated by the membrane transport protein ABCC1 in mice. Journal of Clinical Investigation 121, 3924–3931.
158. Kumar, R. & Thompson, E. B. (2003). Transactivation functions of the N-terminal domains of nuclear hormone receptors: protein folding and coactivator interactions. Molecular Endocrinology 17, 1–10.
159. Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., Krafft, G. A. & Klein, W. L. (2004). Synaptic targeting by Alzheimer's-related amyloid beta oligomers. Journal of Neuroscience 24, 10191–10200.
160. LaFerla, F. M. (2012). Preclinical success against Alzheimer's disease with an old drug. New England Journal of Medicine 367, 570–572.
161. Lago, R. M., Singh, P. P. & Nesto, R. W. (2007). Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized clinical trials. Lancet 370, 1129–1136.
162. Landreth, G. (2006). PPARgamma agonists as new therapeutic agents for the treatment of Alzheimer's disease. Experimental Neurology 199, 245–248.
163. Landreth, G. (2007). Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease. Current Alzheimer Research 4, 159–164.
164. Landreth, G. E. & Heneka, M. T. (2001). Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiology of Aging 22, 937–944.
165. Lashuel, H. A., Petre, B. M., Wall, J., Simon, M., Nowak, R. J., Walz, T. & Lansbury, P. T. Jr. (2002). Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. Journal of Molecular Biology 322, 1089–1102.
166. Latruffe, N., Malki, M. C., Nicloas-Frances, V., Clemencet, M. C., Jannin, B. & Berlot, J. P. (2000). Regulation of the peroxisomal beta-oxidation-dependent pathway by peroxisome proliferator-activated receptor alpha and kinases. Biochemical Pharmacology 60, 1027–1032.
167. Laudet, V., Hännni, C., Coll, J., Catzeflis, F. & Stéhelin, D. (1992). Evolution of the nuclear receptor gene superfamily. EMBO Journal 11, 1003–1013.
168. Lazarow, P. B. & De Duve, C. (1976). A fatty acyl-CoA oxidizing system in rat liver peroxisomes; enhancement by clofibrate, a hypolipidemic drug. Proceedings of the National Academy of Sciences of the United States of America 73, 2043–2046.
169. Lecka-Czernik, B., Moerman, E. J., Grant, D. F., Lehmann, J. M., Manolagas, S. C. & Jilka, R. L. (2002). Divergent effects of selective peroxisome proliferator-activated receptor-γ2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 143, 2376–2384.
170. Lee, C. H., Chawla, A., Urbiztondo, N., Liao, D., Boisvert, W. A., Evans, R. M. & Curtiss, L. K. (2003). Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 302, 453–457.
171. Lee, G., Elwood, F., McNally, J., Weiszmann, J., Lindstrom, M., Amaral, K., Nakamura, M., Miao, S., Cao, P., Learned, R. M., Chen, J. L. & Li, Y. (2002). T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. Journal of Biological Chemistry 277, 19649–19657.
172. Lee, D. H., Huang, H., Choi, K., Mantzoros, C. & Kim, Y. B. (2012). Selective PPARγ modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice. American Journal of Physiology. Endocrinology and Metabolism 302, E552–560.
173. Lee, S. S., Pineau, T., Drago, J., Lee, E. J., Owens, J. W., Kroetz, D. L., Fernandez-Salguero, P. M., Westphal, H. & Gonzales, F. J. (1995). Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Molecular and Cellular Biology 15, 3012–3022.
174. Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M. & Kliewer, S. A. (1997). Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. Journal of Biological Chemistry 272, 3406–3410.
175. Leng, Y., Wang, Z., Tsai, L. K., Leeds, P., Fessler, E. B., Wang, J. & Chuang, D. M. (2014). FGF-21, a novel metabolic regulator, has a robust neuroprotective role and is markedly elevated in neurons by mood stabilizers. Molecular Psychiatry 20, 215–223.
176. Li, M., Pascual, G. & Glass, C. K. (2000). Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Molecular and Cellular Biology 20, 4699–4707.
177. Li, S., Shankar, G. M. & Selkoe, D. J. (2010). How do soluble oligomers of amyloid beta-protein impair hippocampal synaptic plasticity? Frontiers in Cellular Neuroscience 4, 5.
178. Li, W., Zhang, J. W., Lu, F. & Ma, M. M. (2012). Effects of telmisartan on the level of Aβ1-42, interleukin-1β, tumor necrosis factor α and cognition in hypertensive patients with Alzheimer's disease. Zhonghua Yi Xue Za Zhi 92, 2743–2746.
179. Liu, C. & Lin, J. D. (2011). PGC-1 coactivators in the control of energy metabolism. Acta Biochimica et Biophysica Sinica 43, 248–257.
180. Lock, E. A., Mitchell, A. M. & Elcombe, C. R. (1989). Biochemical mechanisms of induction of hepatic peroxisome proliferation. Annual Review of Pharmacology and Toxicology 29, 145–163.
181. Lovett-Racke, A. E., Hussain, R. Z., Northrop, S., Choy, J., Rocchini, A., Matthes, L., Chavis, J. A., Diab, A., Drew, P. D. & Racke, M. K. (2004). Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. Journal of Immunology 172, 5790–5798.
182. Malm, T., Mariani, M., Donovan, L. J., Neilson, L. & Landreth, G. E. (2015). Activation of the nuclear receptor PPARdelta is neuroprotective in transgenic mouse model of Alzheimer's disease theough inhibition of inflammation. Journal of Neuroinflammation 12, 7.
183. Manczak, M., Anekonda, T. S., Henson, E., Park, B. S., Quinn, J. & Reddy, P. H. (2006). Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Human Molecular Genetics 15, 1437–1449.
184. Mandrekar-Colucci, S., Karlo, J. C. & Landreth, G. E. (2012). Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. Journal of Neuroscience 32, 10117–10128.
185. Mangelsdorf, D. J., Borgmeyer, U., Heyman, R. A., Zhou, J. Y., Ong, E. S., Oro, A. E., Kakizuka, A. & Evans, R. M. (1992). Characerization of the three RXR genes that mediate the action of 9-cis retinoic acid. Genes & Development 6, 329–344.
186. Mangelsdorf, D. J. & Evans, R. M. (1995). The RXR heterodimers and orphan receptors. Cell 83, 841–850.
187. Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Scütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P. & Evans, R. M. (1995). The nuclear receptor superfamily: the second decade. Cell 83, 835–839.
188. Manji, H., Kato, T., Di Prospero, N. A., Ness, S., Beal, M. F., Krams, M. & Chen, G. (2012). Impaired mitochondrial function in psychiatric disorders. Nature Reviews Neuroscience 13, 293–307.
189. Martin, E., Betuing, S., Pagès, C., Cambon, K., Auregan, G., Deglon, N., Roze, E. & Caboche, J. (2011). Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role of chromatin remodeling at the PGC-1-alpha promoter. Human Molecular Genetics 20, 2422–2434.
190. Martin, H. L., Mounsey, R. B., Mustafa, S., Sathe, K. & Teismann, P. (2012). Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson's disease. Experimental Neurology 235, 528–538.
191. Martín, A., Pérez-Girón, J. V., Hernanz, R., Palacios, R., Briones, A. M., Fortuño, A., Zalba, G., Salaices, M. & Alonso, M. J. (2012). Peroxisome proliferator-activated receptor-γ activation reduces cyclooxygenase-2 expression in vascular smooth muscle cells from hypertensive rats by interfering with oxidative stress. Journal of Hypertension 30, 315–326.
192. Martinasso, G., Oraldi, M., Tromabetta, A., Maggiora, M., Bertetto, O., Canuto, R. A. & Muzio, G. (2007). Involvement of PPARs in cell proliferation and apoptosis in human colon cancer specimens and in normal and cancer cell lines. PPAR Research 2007, 93416.
193. Masters, C. & Crane, D. (1998). On the role of the peroxisome in cell differentiation and carcinogenesis. Molecular and Cellular Biochemistry 187, 85–97.
194. Mayeux, R. & Stern, Y. (2012). Epidemiology of Alzheimer disease. Cold Spring Harbor Perspectives in Medicine 2, a006239.
195. McFarland, K., Spalding, T. A., Hubbard, D., Ma, J. N., Olsson, R. & Burstein, E. S. (2013). Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson's disease. ACS Chemical Neuroscience 4, 1430–1438.
196. McGeer, P. L. & McGeer, E. G. (2007). Glial reactions in Parkinson's disease. Movement Disorders 23, 474–483.
197. McKenna, N. J., Xu, J., Nawaz, Z., Tsai, S. Y. & O'Malley, B. W. (1999). Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions. Journal of Steroid Biochemistry and Molecular Biology 69, 3–12.
198. Minghetti, L. (2004). Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. Journal of Neurpathology and Experimental Neurology 63, 901–910.
199. Minghetti, L. (2007). Role of COX-2 in inflammatory and degenerative brain diseases. Subcellular Biochemistry 42, 127–141.
200. Miyata, K. S., McCaw, S. E., Marcus, S. L., Rachubinski, R. A. & Capone, J. P. (1994). The peroxisome proliferator-activated receptor interacts with the retinoid X receptor in vivo. Gene 148, 327–330.
201. Moody, D. E. & Reddy, J. K. (1978). The hepatic effects of hypolipidemic drugs (colfibrate, nafenopin, tibric acid, and, y-14,643) on hepatic peroxisomes and peroxisome-associated enzymes. The American Journal of Pathology 90, 435–446.
202. Moraes, L. A., Piqueras, L. & Bishop-Bailey, D. (2006). Peroxisome proliferator-activated receptors and inflammation. Pharmacology and Therapeutics 110, 371–385.
203. Moreno, S., Farioli-Vacchioli, S. & Ceru, M. P. (2004). Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 123, 131–145.
204. Morgan, L., Shah, B., Rivers, L. E., Barden, L., Groom, A. J., Chung, R., Higazi, D., Desmond, H., Smith, T. & Staddon, J. M. (2007). Inflammation and dephosphorylation of the tight junction protein occluding in an experimental model of multiple sclerosis. Neuroscience 147, 664–673.
205. Mori, H., Okada, Y., Arao, T., Nishida, K. & Tanaka, Y. (2012). Telmisartan at 80 mg/day increases high-molecular- weight adiponectin levels and improves insulin resistance in diabetic patients. Advances in Therapy 29, 635–644.
206. Motani, A., Wang, Z., Weiszmann, J., McGee, L. R., Lee, G., Liu, Q., Staunton, J., Fang, Z., Fuentes, H., Lindstrom, M., Liu, J., Biermann, D. H., Jaen, J., Walker, N. P., Learned, R. M., Chen, J. L. & Li, Y. (2009). INT131: a selective modulator of PPAR gamma. Journal of Molecular Biology 386, 1301–1311.
207. 2-protein: synaptic and network dysfunction. Cold Spring Harbor Perspective in Medicine 2, a006338.
208. Mukherjee, R., Jow, L., Croston, G. E. & Paterniti, J. R. Jr. (1997). Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. Journal of Biological Chemistry 272, 8071–8076.
209. Mulholland, D. J., Dedhar, S., Coetzee, G. A. & Nelson, C. C. (2005). Interaction of nuclear receptors with the Wnt/β-catenin/Tcf signaling axis: Wnt you like to know? Endocrine Reviews 26, 898–915.
210. Murakami, K., Wada, J., Ogawa, D., Horiguchi, C. S., Miyoshi, T., Sasaki, M., Uchida, H. A., Nakamura, Y. & Makino, H. (2012). The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: abdominal fat depot intervention program of Okayama (ADIPO). Diabetes & Vascular Disease Research 10, 93–96.
211. Neher, M. D., Weckbach, S., Huber-Lang, M. S. & Stahel, P. F. (2012). New insights into the role of peroxisome proliferator-activated receptors in regulating the inflammatory response after tissue injury. PPAR Research 2012, 728461.
212. Nenov, M. N., Tempia, F., Denner, L., Dineley, K. T. & Laezza, F. (2015). Impaired firing properties of dentate granule neurons in an Alzheimer's disease animal model are rescued by PPARgamma agonism. Journal of Neurophysiology 113, 1712–1726.
213. Nettles, K. W. (2008). Insights into PPARγ from structures with endogenous and covalently bound ligands. Nature Structural & Molecular Biology 15, 893–895.
214. Neumann, H. (2001). Control of glial immune function by neurons. Glia 36, 191–199.
215. Nikolaidis, L. A. & Levine, T. B. (2004). Peroxisome proliferator activator receptors (PPAR), insulinresistance, and cardiomyopathy: friends or foes for the diabetic patient with heart failure? Cardiology in Review 12, 158–170.
216. Ninds Exploratory Trials in Parkinsons Disease (NET-PD) FS-ZONE Investigators (2015). Pioglitazone in early Parkinson's disease: a phase 2, multicenter, double-blind, randomized trial. Lancet Neurology 14, 795–803.
217. Nissen, S. E. & Wolski, K. (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. The New England Journal of Medicine 356, 2457–2471.
218. Noe, N., Dillon, L. l., Lellek, V. & Diaz, F. (2013). Bezafibrate improves mitochondrial function in the CNS of a mouse model of mitochondrial encephalopathy. Mitochondrion 13, 417–426.
219. Nolan, Y. M., Sullivan, A. M. & Toulouse, A. (2013). Parkinson's disease in the nuclear age of neuroinflammation. Trends in Molecular Medicine 19, 187–196.
220. Ohshima, T., Koga, H. & Shimotohno, K. (2004). Transcriptional activity of peroxisome proliferator-activated receptor gamma is modulated by SUMO-1 modification. Journal of Biological Chemistry 279, 29551–29557.
221. Okuma, T., Honda, R., Ichikawa, G., Tsumagari, N. & Yasuda, H. (1999). In vitro SUMO-1 modification requires two enxymatic steps, E1 and E2. Biochemical and Biophysical Research Communications 254, 693–698.
222. Oliva, C. A., Vargas, J. Y. & Inestrosa, N. C. (2013). Wnt signaling: role in LTP, neural networks and memory. Ageing Research Reviews 12, 786–800.
223. Oshima, Y. (2011). Characteristics of drug-associated rhabdomyolysis: analysis of 8,610 cases reported to the U.S. Food and Drug Administration. Internal Medicine 50, 845–853.
224. Owen, G. I. & Zelent, A. (2000). Origins and evolutionary diversification of the nuclear receptor superfamily. Cellular and Molecular Life Science 57, 809–827.
225. Pahl, H. L. (1999). Activators and target genes of Ref/NF-kappaB transcription factors. Oncogene 18, 6853–6866.
226. Pan, J., Jin, J. L., Ge, H. M., Yin, K. L., Chen, X., Han, L. J., Chen, Y., Qian, L., Li, X. X. & Xu, Y. (2015). Malibatol A regulates microglia M1/M2 polarization in experimental stroke in a PPARγ-dependent manner. Journal of Neuroinflammation 12, 51.
227. Parker, M. G. & White, R. (1996). Nuclear receptors spring into action. Nature Structural Biology 3, 113–115.
228. Pascual, G., Fong, A. L., Ogawa, S., Gamliel, A., Li, A. C., Perissi, V., Rose, D. W., Willson, T. M., Rosenfeld, M. G. & Glass, C. K. (2005). A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437, 759–763.
229. Paterniti, I., Impellizzeri, D., Crupi, R., Morabito, R., Campolo, M., Esposito, E. & Cuzzocrea, S. (2013). Molecular evidence for the involvement of PPAR-δ and PPAR-γ in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma. Journal of Neuroinflammation 10, 20.
230. Paula-Lima, A. C., Adasme, T., Sanmartin, C., Sebollela, A., Hetz, C., Carrasco, M. A., Ferreira, S. T. & Hidalgo, C. (2011). Amyloid β-peptide oligomers stimulate RyR-mediated Ca2+ release inducing mitochondrial fragmentation in hippocampal neurons and prevent RyR-mediated dendritic spine remodeling produced by BDNF. Antioxidants & Redox Signaling 14, 1209–1223.
231. Peraldi, P., Xu, M. & Spiegelman, B. M. (1997). Thizolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. Journal of Clinical Investigation 100, 1863–1869.
232. Peraza, M. A., Burdick, A. D., Marin, H. E., Gonzalez, F. J. & Peters, J. M. (2006). The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicological Sciences 90, 269–295.
233. Pérez, E., Bourguet, W., Gronemeyer, H. & De Lera, A. R. (2012). Modulation of RXR function through ligand design. Biochimica et Biophysica Acta 1821, 57–69.
234. Perl, D. P. (2010). Neuropathology of Alzheimer's disease. Mount Sinai Journal of Medicine 77, 32–42.
235. Peters, J. M., Cheung, C. & Gonzales, F. J. (2005). Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand? Journal of Molecular Medicine 83, 774–785.
236. Picard, F., Kurtev, M., Chung, N., Topark-Ngarm, A., Senawong, T., Machado de Oliveira, R., Leid, M., McBurney, M. W. & Guarente, L. (2004). Sirt1 promotes fat mobilization in with adipocytes by repressing PPAR-gamma. Nature 429, 771–776.
237. Pierrot, N., Lhommel, R., Quenon, L., Hanseeuw, B., Dricot, L., Sindic, C., Maloteaux, J. M., Octavea, J. N. & Ivanoiu, A. (2015). Targretin improves cognitive and biological markers in a patient with Alzheimer's disease. Journal of Alzheimer's Disease 49, 271–276.
238. Platta, H. W., Hagen, S. & Erdmann, R. (2013). The exportomer: the peroxisomal receptor export machinery. Cellular and Molecular Life Sciences 70, 1393–1411.
239. Polvani, S., Tarocchi, M. & Galli, A. (2012). PPARγ and oxidative stress: con(β) catenating NRF2 and FOXO. PPAR Research 2012, 641087.
240. Pourcet, B., Pineda-Torra, I., Derudas, B., Staels, B. & Gilneur, C. (2010). SUMOylation of human peroxisome proliferator-activated receptor alpha inhibits its trans-activity through the recruitment of the nuclear corepressor NCoR. Journal of Biological Chemistry 285, 5983–5992.
241. Prakash, A. & Kumar, A. (2013). Pioglitazone alleviates the mitochondrial apoptotic pathway and mito-oxidative damage in the d-galactose-induced mouse model. Clinical and Experimental Pharmacology and Physiology 40, 644–651.
242. Puigserver, P., Wu, Z., Park, C. W., Graves, R., Wright, M. & Spiegelman, B. M. (1998). A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92, 829–839.
243. Qi, Y., Yin, X., Wang, S., Jiang, H., Wang, X., Ren, M., Su, X. P., Lei, S. & Feng, H. (2015). PGC-1α silencing compunds the perturbation of mitochondrial function caused by mutant SOD1 in skeletal muscle of ALS mouse model. Frontiers in Aging Neuroscience 7, 204.
244. Qin, W., Haroutunian, V., Katsel, P., Cardozo, C. P., Ho, L., Buxbaum, J. D. & Pasinetti, G. M. (2009). PGC-1α expression decreases in the Alzheimer disease brain as function of dementia. Archives of Neurology 66, 352–361.
245. Ramirez, S. H., Heilman, D., Morsey, B., Potula, R., Haorah, J. & Persidsky, Y. (2008). Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) suppresses Rho GTPases in human brain microvascular endothelial cells and inhibits adhesion and transendothelial migration of HIV-1 infected monocytes. Journal of Immunology 180, 1854–1865.
246. Rannou, F., Francois, M., Corvol, M. T. & Berenbaum, F. (2006). Cartilage breakdown in rheumatoid arthritis. Joint, Bone, Spine 73, 29–36.
247. Rao, M. S. & Reddy, J. K. (1996). Hepatocarcinogenesis of peroxisome proliferators. Annals of the New York Academy of Science 804, 573–587.
248. Ravaux, L., Denoyelle, C., Monne, C., Limon, I., Raymondjean, M. & El Hadri, K. (2007). Inhibition of interleukin-1 beta-induced group IIA secretory phospholipase A2 expression by peroxisome proliferator-activated receptors (PPARs) in rat vascular smooth muscle cells: cooperation between PPARbeta and the proto-oncogene BCL-6. Molecular and Cellular Biology 27, 8374–8387.
249. Reddy, J. K. (1974). Hepatic microbody proliferation and catalase synthesis induced by methyl clofenapate, a hypilipidemic analog of CPIB. American Journal of Pathology 75, 103–118.
250. Reddy, J. K., Azarnoff, D. L. & Hignite, C. E. (1980). Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature 283, 397–398.
251. Reddy, J. K., Azarnoff, D. L., Svoboda, D. J. & Prasad, J. D. (1974). Nafenopin-induced hepatic microbody (peroxisome) proliferation and catalase synthesis in rats and mice. Absence of sex difference in response. Journal of Cell Biology 61, 344–385.
252. Reddy, P. H. & Beal, M. F. (2008). Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline and Alzheimer's disease. Trends in Molecular Medicine 14, 45–53.
253. Reddy, J. K., Goel, S. K., Nemali, M. R., Carrino, J. J., Laffler, T. G., Reddy, M. K., Sperbeck, S. J., Osumi, T., Hashimoto, T. & Lalwani, N. D. (1986). Transcription regulation of peroxisomal fatty acyl-CoA oxidase and enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase in rat liver by peroxisome proliferators. Proceedings of the National Academy of Sciences of the United States of America 83, 1747–1751.
254. Reddy, J. K. & Hashimoto, T. (2001). Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptative metabolic system. Annual Review of Nutrition 21, 193–230.
255. Ricote, M., Huang, J. T., Welch, J. S. & Glass, C. K. (1999). The peroxisome proliferator-activated receptor (PPARgamma) as a regulator of monocyte/macrophage function. Journal of Leukocyte Biology 66, 733–739.
256. Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J. & Glass, C. K. (1998). The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391, 79–82.
257. Rios, J. A., Cisternas, P., Arrese, M., Barja, S. & Inestrosa, N. C. (2014). Is Alzheimer's disease related to metabolic syndrome? A Wnt signaling conundrum. Progress in Neurobiology 121, 125–146.
258. Rizzo, G. & Fiorucci, S. (2006). PPARs and other nuclear receptors in inflammation. Current Opinion in Pharmacology 6, 421–427.
259. Rogers, J., Mastroeni, D., Leonard, B., Joyce, J. & Grover, A. (2007). Neuroinflammation in Alzheimer's disease and Pakinson's disease: are microglia pathogenic in either disorder? International Review of Neurobiology 82, 235–246.
260. Rojo, L. E., Fernandez, J. A., Maccioni, A. A., Jimenez, J. M. & Maccioni, R. B. (2008). Neurinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Archives of Medical Research 39, 1–16.
261. Rosen, E. D., Sarraf, P., Troy, A. E., Bradwin, G., Moore, K., Milstone, D. S., Spiegelman, B. M. & Mortensen, R. M. (1999). PPAR gamma I srequired for the differentiation of adipose tissue in vivo and in vitro. Molecular Cell 4, 611–617.
262. Rosenberg, G. A. & Mun-Bryce, S. (2004). Matrix metalloproteinases in neuroinflammation and cerebral ischemia. In Neuroinflammation in stroke (eds. U. Dirnagl and B. Elger), Ernst Schering Research Foundation Workshop 47, pp. 1–16.
263. Rosenson, R. S., Wright, R. S., Farkouh, M. & Plutzky, J. (2012). Modulating peroxisome proliferator–activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. American Heart Journal 164, 672–680.
264. Roth, A. D., Leisewitz, A. V., Jung, J. E., Cassina, P., Barbeito, L., Inestrosa, N. C. & Bronfman, M. (2003). PPAR gamma activators induce growth arrest and process extension in B12 oligodendrocyte-like cells and terminal differentiation of cultured oligodendrocytes. Journal of Neuroscience Research 72, 425–435.
265. Roy, A., Jana, M., Kundu, M., Corbett, G. T., Rangaswamy, S. B., Mishra, R. K., Luan, C.-H., González, F. J. & Pahan, K. (2015). HMG-CoA reductase inhibitors bind to PPARA to upregulate neurotrophin expression in the brain and improve memory in mice. Cell Metabolism 22, 253–265.
266. Rubenstrunk, A., Hanf, R., Hum, D. W., Fruchart, J. C. & Stael, B. (2007). Safety issues and prospects for future generations of PPAR modulators. Biochimica et Biophysica Acta 1777, 1065–1081.
267. Sáez, P. J., Lange, S., Pérez-Acle, T. & Owen, G. I. (2010). Nuclear receptor genes: evolution. In Encyclopedia of Life Sciences. John Wiley & Sons, Ltd, Chichester http://www.els.net [doi: 10.1002/9780470015902.a0006145.pub3].
268. Saijo, K., Crotti, A. & Glass, C. K. (2013). Regulation of microglia and deactivation by nuclear receptors. Glia 61, 104–111.
269. Salma, N., Xiao, H., Mueller, E. & Imbalzano, A. N. (2004). Temporal recruitment of transcription factors and SWI/SNF chromatin-remodeling enzymes during adipogenic induction of the peroxisome proliferator-activated receptor gamma nuclear hormone receptor. Molecular and Cellular Biology 24, 4651–4663.
270. Salmon, D. P. & Bondi, M. W. (2009). Neuropsychological assessment of dementia. Annual Review of Psychology 60, 257–282.
271. Santos, M. J., Quintanilla, R. A., Toro, A., Grandy, R., Dinamarca, M. C., Godoy, J. A. & Inestrosa, N. C. (2005). Peroxisomal proliferation protects from beta-amyloid neurodgeneration. Journal of Biological Chemistry 280, 41057–41068.
272. Sastre, M., Dewachter, I., Landreth, G. E., Willson, T. M., Klockgether, T., Van Leuven, F. & Heneka, M. T. (2003). Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. Journal of Neuroscience 23, 9796–9804.
273. Satoh, K., Hata, M., Takahara, S., Tsuzaki, H., Yokota, H., Akatsu, H., Yamamoto, T., Kosaka, K. & Yamada, T. (2006). A novel membrane protein, encoded by the gene covering KIA A0233, is transcriptionally induced by senile plaque-associated astrocytes. Brain Research 1108, 19–27.
274. Savva, G. M., Wharton, S. B., Ince, P. G., Forster, G., Matthews, F. E., Brayne, C. & Medical Research Council Cognitive Function and Ageing Study (2009). Age, neuropathology, and dementia. The New England Journal of Medicine 360, 2302–2309.
275. Scheff, S. W., Price, D. A., Schmitt, F. A., DeKosky, S. T. & Mufson, E. J. (2007). Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 68, 1501–1508.
276. Schintu, N., Frau, L., Ibba, M., Caboni, P., Garau, A., Carboni, E. & Carta, A. R. (2009). PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. European Journal of Neuroscience 29, 954–963.
277. Schnegg, C. I., Kooshki, M., Hsu, F. C., Sui, G. & Robbins, M. E. (2012). PPARδ prevents radiation-induced proinflammatory responses in microglia via transrepression of NF-κB and inhibition of the PKCα/MEK1/2/ERK1/2/AP-1 pathway. Free Radical Biology and Medicine 52, 1734–1743.
278. Schnegg, C. I. & Robbins, M. E. (2011). Neuroprotective mechanisms of PPARδ: modulation of oxidative stress and inflammatory processes. PPAR Research 2011, 373560.
279. Schoonjans, K., Watanabe, M., Suzuki, H., Mahfoudi, A., Krey, G., Wahli, W., Grimaldi, P., Staels, B., Yamamoto, T. & Auwerx, J. (1995). Induction of the acyl-coenzyme A synthase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. Journal of Biological Chemistry 270, 19269–19276.
280. Schultzberg, M., Lindberg, C., Aronsson, A. F., Hjorth, E., Spulber, S. D. & Oprica, M. (2007). Inflammation in the nervous system—physiological and pathophysiological aspects. Physiology and Behavior 92, 121–128.
281. Sears, D. D., Hsiao, A., Ofrecio, J. M. & Chapman, J. (2007). Selective modulation of promoter recruitment and transcriptional activity of PPARγ. Biochemical and Biophysical Research Communications 364, 515–521.
282. Selkoe, D. J. (2001). Alzheimer's disease: genes, proteins, and therapy. Physiological Reviews 81, 741–766.
283. Serrano-Pozo, A., Frosch, M. P., Masliah, E. & Hyman, B. T. (2011). Neuropathological alterations in Alzheimer disease. Cold Spring Harbor Perspectives in Biology 3, a006189.
284. Sertzing, P., Seifert, M., Tilgen, W. & Reichrath, J. (2007). Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. Journal of Cellular Physiology 212, 1–12.
285. Shaerzadeh, F., Motamedi, F., Minai-Tehrani, D. & Khodagholi, F. (2013). Monitoring of neuronal loss in the hippocampus of Aβ-injected rat: autophagy, mitophagy, and mitochondrial biogenesis stand against apoptosis. Neuromolecular Medicine 16, 175–190.
286. Shalev, A., Siegrist-Kaiser, C. A., Yen, P. M., Wahli, W., Burger, A. G., Chin, W. W. & Meier, C. A. (1996). The peroxisome proliferator-activated receptor alpha is a phosphoprotein: regulation by insulin. Endocrinology 137, 4499–4502.
287. Sharma, A. M. & Staels, B. (2007). Review: peroxisome proliferator-activated receptor gamma and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. Journal of Clinical Endocrinology & Metabolism 92, 386–395.
288. Shearer, B. G. & Hoekstra, W. J. (2003). Recent advances in peroxisome proliferator-activated receptor science. Current Medicinal Chemistry 10, 267–280.
289. Sheng, M., Sabatini, B. L. & Südhof, T. C. (2012). Synapses and Alzheimer's Disease. Cold Spring Harbor Perspectives in Biology 4, a005777.
290. Shibata, N., Motoi, Y., Tomiyama, H., Ohnuma, T., Kuerban, B., Tomson, K., Komatsu, M., Shimazaki, H., Hattori, N. & Arai, H. (2013). Lack of genetic associations of PPAR-γ and PGC-1α with Alzheimer's disease and Parkinson's disease with dementia. Dementia and Geriatric Cognitive Disorders Extra 3, 161–167.
291. Shimizu, K., Mitchell, R. N. & Libby, P. (2006). Inflammation and cellular immune responses in abdominal aortic aneurysms. Arteriosclerosis, Thrombosis, and Vascular Biology 26, 987–994.
292. Shin, J. H., Ko, H. S., Kang, H., Lee, Y., Lee, Y. I., Pletinkova, O., Troconso, J. C., Dawson, V. L. & Dawson, T. M. (2011). PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease. Cell 144, 689–702.
293. Singh, S., Loke, Y. K. & Furberg, C. D. (2007). Long-term risk of cardiovascular events with Rosiglitazone. A meta-analysis. Journal of the American Medical Association 298, 1189–1195.
294. Skaper, S. D. (2007). The brain as a target for inflammatory processes and neuroprotective strategies. Annals of the New York Academy of Science 1122, 23–34.
295. Skerrett, R., Malm, T. & Landreth, G. (2014). Nuclear receptors in neurodegenerative diseases. Neurobiology of Disease 72, 104–116.
296. Skerrett, R., Pellegrino, M. P., Casali, B. T., Taraboanta, L. & Landreth, G. E. (2015). Combined liver X receptor/peroxisome proliferator-activated receptor γ agonist treatment reduces amyloid β levels and improves behavior in amyloid precursor protein/presenilin 1 mice. Journal of Biological Chemistry 290, 21591–21602.
297. Stahel, P. F., Smith, W. R., Bruchis, J. & Rabb, C. H. (2008). Peroxisome proliferator-activated receptors: “key” regulators of neuroinflammation after traumatic brain injury. PPAR Research 2008, 538141.
298. Step, S. E., Lim, H.-W., Marinis, J. M., Prokesch, A., Steger, D. J., You, S.-H., Won, K.-J. & Lazar, M. A. (2014). Anti-diabetic rosiglitazone remodels the adipocyte transcriptome by redistributing transcription to PPARγ-driven enhancers. Genes & Development 28, 1018–1028.
299. Storer, P. D., Xu, J., Chavis, J. & Drew, P. D. (2005). Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. Journal of Neuroimmunology 161, 113–122.
300. Südhof, T. C. (2012). The presynaptic active zone. Neuron 75, 11–25.
301. Südhof, T. C. (2013). Neurotransmitter release: the last millisecond in the life of a synaptic vesicle. Neuron 80, 675–690.
302. Tachibana, M., Shinohara, M., Yamazaki, Y., Liu, C. C., Rogers, J., Bu, G. & Kanekiyo, T. (2015). Rescuing effects of RXR agonist bexarotene on aging-related synapse loss depend on neuronal LRP1. Experimental Neurology 277, 1–9.
303. Takizawa, T., Murakami, K., Yano, W., Abe, K., Mizoguchi, T., Yamazaki, H., Asasuma, A., Tanabe, S., Hennuyer, N., Staels, B. & Fruchart, J. C. (2012). K-877, a highly potent and selective PPARa agonist, improves dyslipidemia and atherosclerosis in experimental animal models. In The 80th EAS Congress. Milan, Italy May 2012.
304. Tan, Z. S., Beiser, A. S., Vasan, R. S., Roubenoff, R., Dinarello, C. A., Harris, T. B., Benjamin, E. J., Au, R., Kiel, D. P., Wolf, P. A. & Seshadri, S. (2007). Inflammatory markers and the risk of Alzheimer disease: the Framingham study. Neurology 68, 1902–1908.
305. Tansey, M. G., Frank-Cannon, T. C., McCoy, M. K., Lee, J. K., Martinez, T. N., McAlpine, F. E., Ruhn, K. A. & Tran, T. A. (2008). Neuroinflammation in Parkinson's disease: is there sufficient evidence for mechanism-based interventional therapy? Frontiers in Bioscience 13, 709–717.
306. Taoufik, E., Tseveleki, V., Euagelidou, M., Emmanouil, M., Voulgari-Kokota, A., Haralambous, S. & Probert, L. (2008). Positive and negative implications of tumor necrosis factor neutralization for the pathogenesis of multiple sclerosis. Neurodegenerative Diseases 5, 32–37.
307. Taygerly, J. P., McGee, L. R., Rubenstein, S. M., Houze, J. B., Cushing, T. D., Li, Y., Motani, A., Chen, J. L., Frankmoelle, W., Ye, G., Learned, M. R., Jaen, J., Miao, S., Timmermans, P. B., Thoolen, M., Kearney, P., Flygare, J., Beckmann, H., Weiszmann, J., Lindstrom, M., Walker, N., Liu, J., Biermann, D., Wang, Z., Hagiwara, A., Iida, T., Aramaki, H., Kitao, Y., Shinkai, H., Furukawa, N., Nishiu, J. & Nakamura, M. (2013). Discovery of INT131: a selective PPARγ modulator that enhances insulin sensitivity. Bioorganic & Medicinal Chemistry 21, 979–992.
308. Tenbaum, S. & Baniahmad, A. (1997). Nuclear receptors: structure, function and involvement in disease. The International Journal of Biochemistry & Cell Biology 29, 1325–1341.
309. Tenenbaum, A. & Fisman, E. Z. (2012). Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Cardiovascular Diabetology 11, 140.
310. Thummel, C. S. (1995). From embryogenesis to metamorphosis: the regulation and function of Drosophila nuclear receptor superfamili members. Cell 83, 871–877.
311. Totland, G. K., Madsen, L., Klementsen, B., Vaagenes, H., Kryvi, H., Frøyland, L., Hexeberg, S. & Berge, R. K. (2000). Proliferation of mitocondria and gene expression of carnitine plmitoyltransferase and fatty acyl-CoA oxidase in rat skeletal muscle, heart and liver by hypolipidemic fatty acids. Biology of the Cell 92, 317–329.
312. Uppenberg, J., Svensson, C., Jaki, M., Bertilsson, G., Jendeberg, L. & Berkenstam, A. (1998). Crystal structure of the ligan binding domain of the human nuclear receptor PPARgamma. Journal of Biological Chemistry 273, 31108–31112.
313. Vargas, J. Y., Fuenzalida, M. & Inestrosa, N. C. (2014). In vivo activation of Wnt signaling pathway enhances cognitive function of adult mice and reverses cognitive deficits in an Alzheimer's disease model. Journal of Neuroscience 34, 2191–2202.
314. Viswakarma, N., Jia, Y., Bai, L., Vluggens, A., Borensztajn, J., Xu, J. & Reddy, J. K. (2010). Coactivators in PPAR-regulated gene expression. PPAR Research 2010, 250126.
315. Wagner, E. F. & Eferl, R. (2005). Fos/AP-1 proteins in bone and the immune system. Immunological Reviews 208, 126–140.
316. Wahli, W., Braissant, O. & Desvergne, B. (1995). Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more…. Chemistry & Biology 2, 261–266.
317. Wahli, W., Devchand, P. R., Ijpenberg, A. & Desvergne, B. (1999). Fatty acids, eicosanoids, and hypolipidemic agents regulate gene expression through direct binding to peroxisome proliferator-activated receptors. Advances in Experimental Medicine and Biology 447, 199–209.
318. Waite, K. J., Floyd, Z. E., Arbour-Reily, P. & Stephens, J. M. (2001). Interferon-gamma-induced regulation of peroxisome proliferator-activated receptor gamma and STATs in adipocytes. Journal of Biological Chemistry 276, 7062–7068.
319. Wang, R., Li, J. J., Diao, S., Kwak, Y. D., Liu, L., Zhi, L., Büeler, H., Bhat, N. R., Williams, R. W., Park, E. A. & Liao, F. F. (2013). Metabolic stress modulates Alzheimer's β-secretase gene transcription via SIRT1-PPARγ-PGC-1 in neurons. Cell Metabolism 17, 685–694.
320. Wareski, P., Vaarmann, A., Choubey, V., Safiulina, D., Liiv, J., Kuum, M. & Kaasik, A. (2009). PGC-1α and PGC-1β regulate mitochondrial density in neurons. Journal of Biological Chemistry 284, 21379–21385.
321. Watson, G. S. & Craft, S. (2003). The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs 17, 27–45.
322. Wei, H., Kemp, S., McGuinness, M. C., Moser, A. B. & Smith, K. D. (2000). Pharmacological induction of peroxisomes in peroxisome biogenesis disorders. Annals of Neurology 47, 286–296.
323. Weisman, D., Hakimian, E. & Ho, G. J. (2006). Interleukins, inflammation, and mechanisms of Alzheimer's disease. Vitamins & Hormones 74, 505–530.
324. Westermann, B. (2010). Mitochondrial fusion and fission in cell life and death. Nature Reviews Molecular Cell Biology 11, 872–884.
325. Williamson, J. D., Launer, L. J., Bryan, R. N., Coker, L. H., Lazar, R. M., Gerstein, H. C., Murray, A. M., Sullivan, M. K., Horowitz, K. R., Ding, J., Marcovina, S., Lovato, L., Lovato, J., Margolis, K. L., Davatzikos, C., Barzilay, J., Ginsberg, H. N., Linz, P. E., Miller, M. E. & Action to Control Cardiovascular Risk in Diabetes (ACCORD) Memory in Diabetes (MIND) Investigators (2014). Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine 174, 324–333.
326. Willson, T. M., Brown, P. J., Sternbach, D. D. & Henke, B. R. (2000). The PPARs: from orphan receptors to drug discovery. Journal of Medicinal Chemistry 43, 527–550.
327. Wilms, H., Zecca, L., Rosenstiel, P., Sievers, J., Deuschl, G. & Lucius, R. (2007). Inflammation in Parkinson's disease and other neurodegenerative diseases: cause and therapeutic implications. Current Pharmaceutical Design 13, 1925–1928.
328. Woerly, G., Honda, K., Loyens, M., Papin, J. P., Auwerx, J., Staels, B., Capron, M. & Dombrowicz, D. (2003). Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. Journal of Experimental Medicine 198, 411–421.
329. Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., Troy, A., Cinti, S., Lowell, B., Scarpulla, R. C. & Spiegelman, B. M. (1999). Mechanisms controlling mitochondrial biogenesis and respiration through the thermgenic coactivator PGC-1. Cell 98, 115–124.
330. Wurtz, J. M., Bourguet, W., Renaud, J. P., Vivat, V., Chambon, P., Moras, D. & Gronemeyer, H. (1996). A canonical structure for the ligan-binding domain of nuclear receptors. Nature Structural Biology 3, 206.
331. Xu, L., Han, C., Lim, K. & Wu, T. (2006). Cross-talk between peroxisome proliferator-activated receptor delta and cytosolic phospholipase A(2)alpha/cyclooxygenase-2/prostaglandin E(2) signaling pathways in human hepatocellular carcinoma cells. Cancer Research 66, 11859–11868.
332. Xu, H. E., Lambert, M. H., Montana, V. G., Parks, D. J., Blanchard, S. G., Brown, P. J., Sternbach, D. D., Lehmann, J. M., Wisely, G. B., Willson, T. M., Kliewer, S. A. & Milburn, M. V. (1999). Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Molecular Cell 3, 397–403.
333. Xu, S., Liu, G., Bao, X., Wu, J., Li, S., Zheng, B., Anwyl, R. & Wang, Q. (2014). Rosiglitazone prevents amyloid-β oligomer-induced impairment of synapse formation and plasticity via increasing dendrite and spine mitochondrial number. Journal of Alzheimer's Disease 39, 239–251.
334. Xuan, A. G., Chen, Y., Long, D. H., Zhang, M., Ji, W. D., Zhang, W. J., Liu, J. H., Hong, L. P., He, X. S. & Chen, W. L. (2015). PPARα agonist fenofibrate ameliorates learning and memory deficits in rats following global cerebral ischemia. Molecular Neurobiology 52, 601–609.
335. Yamanaka, M., Ishikawa, T., Griep, A., Axt, D., Kummer, M. P. & Heneka, M. T. (2012). PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. Journal of Neuroscience 32, 17321–17331.
336. Yang, X. Y., Wang, L. H., Chen, T., Hodge, D. R., Resau, J. H., DaSilva, L. & Farrar, W. L. (2000). Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. Journal of Biological Chemistry 275, 4541–4544.
337. Yew, T., Toh, S. A. & Millar, J. S. (2012). Selective peroxisome proliferator-activated receptor-γ modulation to reduce cardiovascular risk in patients with insulin resistance. Recent Patents on Cardiovascular Drug Discovery 7, 33–41.
338. Zandbergen, F. & Plutzky, J. (2007). PPPARalpha in atherosclerosis and inflammation. Biochimica et Biophysica Acta 1771, 972–982.
339. Zelcer, N. & Tontonoz, P. (2006). Liver X receptor as integrators of metabolic and inflammatory signaling. Journal of Clinical Investigation 116, 607–614.
340. Zhang, B., Berger, J., Zhou, G., Elbrecht, A., Biswas, S., White-Carrington, S., Szalkowski, D. & Moller, D. E. (1996). Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma. Journal of Biological Chemistry 271, 31771–31774.
341. Zhang, J., Hu, M., Teng, Z., Tang, Y. P. & Chen, C. (2014). Synaptic and cognitive improvements by inhibition of 2-AG metabolism are through upregulation of microRNA-188-3p in a mouse model of Alzheimer's disease. Journal of Neuroscience 34, 14919–14933.
342. Zhang, F., Lavan, B. E. & Gregoire, F. M. (2007). Selective modulators of PPAR-γ activity: molecular aspects related to obesity and side-effects. PPAR Research 2007, 32696.
343. Zhao, Z. Q., Luo, R., Li, L. Y. & Tian, F. S. (2013). Angiotensin II receptor blocker Telmisartan prevents new-onset diabetes in pre-diabetes OLETF rats on a high-fat diet: evidence of anti-diabetes action. Canadian Journal of Diabetes 37, 156–168.
344. Zhu, Y., Alvares, K., Huang, Q., Rao, M. S. & Reddy, J. K. (1993). Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. Journal of Biological Chemistry 268, 26817–26820.
345. Zlokovic, B. V. (2011). Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nature Reviews Neuroscience 12, 723–738.
346. Zolezzi, J. M., Bastías-Candia, S., Santos, M. J. & Inestrosa, N. C. (2014). Alzheimer's disease: relevant molecular and physiopathological events affecting amyloid-β brain balance and the putative role of PPARs. Frontiers in Aging Neuroscience 6, 176.
347. Zolezzi, J. M. & Inestrosa, N. C. (2013). Peroxisome proliferator-activated receptors and Alzheimer's disease: hitting the blood-brain barrier. Molecular Neurobiology 48, 438–451.
348. Zolezzi, J. M., Silva-Alvarez, C., Ordenes, D., Godoy, J. A., Carvajal, F. J., Santos, M. J. & Inestrosa, N. C. (2013). Peroxisome proliferator-activated receptor (PPAR) γ and PPARα agonists modulate mitocondrial fusión-fission dynamics: relevance to reactive oxygen species (ROS)-related neurodegenerative disorders? PLoS One 8, e64019.
349. Zündorf, G. & Reiser, G. (2011). The phosphorylation status of extracellular-regulated kinase 1/2 in astrocytes and neurons from rat hippocampus determines the thrombin-induced calcium release and ROS generation. Journal of Neurochemistry 119, 1194–1204.